medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2018, Number 5

<< Back Next >>

Rev Mex Oftalmol 2018; 92 (5)

Effects of the dexamethasone intravitreal implant (Ozurdex®) on intraocular pressure for the treatment of macular edema

Arrascue S, Rueda J, Unigarro J, Vidal S, Espinosa L, Acosta-Reyes J, Abdala-Caballero C

Language: Spanish
References: 14
Page: 233-238
PDF size: 169.07 Kb.


ABSTRACT

Purpose: To analyze the effects on intraocular pressure (IOP) of the sustained-release dexamethasone implant (Ozurdex ®, Allergan Inc., Irvine, CA, USA) for the treatment of macular edema. Methods: Retrospective study of patients receiving at least one dose of the sustained-release dexamethasone implant between January 2012 and June 2016 in the private retinal practice of a referral center in Barranquilla, Colombia. Ocular hypertension was defined as an IOP ≥ 21 mmHg or an increase of at least 10 mmHg from baseline. The monthly change in IOP during 6 months of follow-up and the relationship with a previous diagnosis of glaucoma was evaluated. Results: Thirty-seven cases were reviewed, with an initial IOP between 9 and 22 mmHg. Hypertension during the 6 months of follow up with topical antihypertensive requirement was observed in 21 cases (56.7%). In 11 cases (29.7%) IOP increased to ≥ 21 mmHg, in 6 (16.2%) it increased ≥ 25 mmHg and, in four cases to ≥ 10 mmHg (10.8%) above the baseline IOP after the 1st month. Likewise, after the 1st month there was an average variation of 3.8 ± 6 mmHg (p = 0.001) and of 1.67 ± 5.6 mmHg (p = 0.002) after the 2nd month. There were no statistical differences in patients with and without previous glaucoma. The highest increase in IOP at the first month was observed in cases with edema due tocentral serous coriorretinopathy (CSC) and Vogt-Koyanagi-Harada (VKH), with a mean of 23 and 21 mmHg respectively; however, this was not statistically significant. Conclusion: A large percentage of patients receiving Ozurdex ® have ocular hypertension (56.7%), requiring management with topical antihypertensive drugs, independently of the history of glaucoma and the etiology of the edema. The highest increase occurred at the 1th month of treatment, remaining at the 2nd and 4th months, with a lower significance in the 6th month after treatment.


REFERENCES

  1. London N, Chiang A, Haller J. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):336-51.

  2. Kapoor K, Wagner M, Wagner A. The sustained release dexamethasone implant: expanding indications in viteoretinal disease. Semin Ophthalmol. 2015;30(30):5-6.

  3. Mansour F. Effect of Corticosteroids Fluid Dynamics. Arch Ophthalmol. 1963;70:482-91.

  4. Ophthalmology AA of. Glaucoma. In: Basic and Clinical Science Course. p. 33-50.

  5. Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM V., Li X-Y, et al. Intraocular Pressure in Patients With Diabetic Macular Edema Treated With Dexamethasone Intravitreal Implant in the 3-Year Mead Study. Retina. 2016;1.

  6. Mazzarella S, Mateo C, Freixes S, Burés-Jelstrup A, Rios J, Navarro R, et al. Effect of Intravitreal Injection of Dexamethasone 0.7 mg (Ozurdex®) on Intraocular Pressure in Patients with Macular Edema. Ophthalmic Res. 2015;54(3):143-9.

  7. Chin E, Almeida D, Velez G, Xu K, Peraire M, Corbella M, et al. Ocular Hypertension After Intravitreal Dexamethasone (Ozurdex) Sustained-Release Implant. Retina. 2016;0(0):1-7.

  8. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology. 2010;117(6):1134-1146.e3.

  9. Malclès A, Dot C, Voirin N, Vié A, Agard É, Bellocq D, et al. Safety of Intravitreal Dexamethasone Implant (Ozurdex). Retina. 2017; 37(7):1352-9.

  10. Lowder C. Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis. Arch Ophthalmol. 2011;129(5):545.

  11. Meyer LM, Schönfeld C-L. Secondary Glaucoma After Intravitreal Dexamethasone 0.7mg Implant in Patients with Retinal Vein Occlusion: A One-Year Follow-Up. J Ocul Pharmacol Ther. 2013;29(6):560-5.

  12. Malclès A, Dot C, Voirin N, Agard É, Vié A, Bellocq D, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: The Reldex Study. Retina. 2016;1-8.

  13. Schmitz K, Maier M, Clemens CR, Höhn F, Wachtlin J, Lehmann F, et al. Zuverlassigkeit und Sicherheit von intravitrealen Ozurdex-Injektionen: Die ZERO-Studie. Ophthalmologe. 2014;111(1):44-52.

  14. Jiménez-Gómez B, González-Montpetit M, Fonollosa Calduch A, Orive Bañuelos A, Valsero Franco S. Efectos de ozurdex en la presión intraocular. Estudio en la práctica clínica. Arch Soc Esp Oftalmol. 2015; 90(9):421-5.




2020     |     www.medigraphic.com